Cingulate Inc. (CING)

$0.97

+0.04 (+4.86%)
Rating:
Recommendation:
-
Symbol CING
Price $0.97
Beta 0.000
Volume Avg. 0.05M
Market Cap 10.970M
Shares () -
52 Week Range 0.664-4.4
1y Target Est -
DCF Unlevered CING DCF ->
DCF Levered CING LDCF ->
ROE 414.84% Strong Buy
ROA -102.26% Strong Sell
Operating Margin -
Debt / Equity 83.79% Buy
P/E -0.45 Neutral
P/B 1.31 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CING news


Healthcare
Biotechnology
NASDAQ Capital Market

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.